Inotek Pharmaceuticals Corp. RCKT 深 沪
等待开盘 11-01 09:30:00 美东时间
3.77
+0.070
+1.89%
华盛通- 最 高3.83
- 今 开3.70
- 成交量 184.31万股
- 最 低 3.64
- 昨 收 3.70
- 总市值 4.07亿
- 52周最高 17.825
- 市盈率 静 --
- 换手率 1.71%
- 52周最低 2.19
- 委 比 28.88%
- 总股本 1.08亿
- 历史最高 67.48
- 量 比 1.28
- 振 幅 5.14%
- 历史最低 2.19
- 每 手 1
- 风险率 4.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insider Moves: Rocket, Fair Isaac, Galaxy, Westinghouse, Fastenal
Insiders have been trading these 5 stocks: (($RCKT)), (($FICO)), (($TSE:GLXY)),...
10-18 21:01
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
The FDA Has Accepted The Resubmission Of Rocket Pharmaceuticals' Marketing Application For Kresladi (Marnetegragene Autotemcel; Marne-cel), An Investigational Gene Therapy For Severe Leukocyte Adhesion Deficiency-I. PDUFA Date Is March 28, 2026
Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary endpoints were met, and KRESLADI was well toleratedRocket is eligible for a Rare Pediatric Disease Priority Review
10-14 19:12
2025 Q3生物制药裁员汇总
（来源：药研网） 金秋十月，凉风拂过，却未能带来行业期盼已久的复苏。 国外媒体Fierce Biotech 最新数据显示，刚过去的第三季度，共发生 62 起裁员...
10-09 14:47
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
10-06 08:35
Rocket Pharmaceuticals Board Member Resigns in September
The latest announcement is out from Rocket Pharmaceuticals ( ($RCKT) ). On Sept...
10-04 05:00
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $7
Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $9 to $7.
10-03 23:15
Rocket Pharmaceuticals Withdraws FDA Application for Gene Therapy
Rocket Pharmaceuticals ( ($RCKT) ) just unveiled an update. On October 3, 2025,...
10-03 19:29
Red Cat Holdings Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Red Cat Holdings, Inc. announced the pricing of an underwritten public offering of 17,968,750 shares of common stock, including 2,343,750 additional shares, raising approximately $172.5 million. Proceeds will be used for general corporate purposes, including its unmanned surface vessel division. Northland Capital Markets acted as sole bookrunner, with Ladenburg Thalmann & Co. Inc. as co-manager. A shelf registration statement was filed with the S...
09-19 16:55
Rocket Pharmaceuticals Announces Dr. Patel’s Departure Agreement
An announcement from Rocket Pharmaceuticals ( ($RCKT) ) is now available. On Se...
09-18 04:52
